Related Experiment Video
Updated: Sep 5, 2025

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
Published on: February 23, 2024
Re-defining iron deficiency in patients with heart failure
J J Cuthbert1,2, N Ransome3, A L Clark2
1Department of Cardiorespiratory Medicine, Centre for Clinical Sciences, Hull York Medical School, University of Hull, Kingston-Upon-Hull, UK.
Iron deficiency in chronic heart failure (CHF) is common and impacts prognosis. Current diagnostic methods may be flawed, suggesting a need for better indicators to guide intravenous iron therapy in CHF patients.
Area of Science:
- Cardiology
- Hematology
- Internal Medicine
Background:
- Iron deficiency (ID) is prevalent in patients with chronic heart failure (CHF), negatively affecting symptoms and outcomes, irrespective of anemia.
- Randomized controlled trials (RCTs) investigating intravenous (IV) iron for ID in CHF have yielded conflicting results.
- This review examines the current understanding and future directions for diagnosing and managing ID in CHF.
Purpose of the Study:
- To review the definition and treatment of iron deficiency in chronic heart failure.
- To evaluate the limitations of current diagnostic criteria for iron deficiency in CHF.
- To explore alternative biomarkers for identifying high-risk patients who may benefit from IV iron.
Main Methods:
- Literature review of existing studies on iron deficiency in chronic heart failure.
- Analysis of current guideline definitions for iron deficiency.
- Evaluation of observational data and alternative diagnostic markers.
Main Results:
- The current definition of ID (serum ferritin <100 µg/L or ferritin 100-299 µg/L and TSAT <20%) is derived from studies in end-stage renal failure and may be inadequate for CHF.
- Inflammatory cytokines in CHF can affect ferritin levels, potentially masking true iron deficiency.
- Observational data suggest the current definition fails to identify a high-risk population in CHF.
Conclusions:
- The existing definition of iron deficiency in CHF may not accurately identify patients who would benefit from IV iron therapy.
- Alternative markers like low serum iron or transferrin saturation (TSAT) may be more effective in identifying at-risk CHF patients.
- Further research is needed to refine diagnostic criteria and optimize IV iron treatment strategies for ID in CHF.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure I: Introduction
Heart Failure II: Pathophysiology

